These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 38325723)

  • 1. Novel CMY-186 variant conferring cross-resistance to cefiderocol and ceftazidime/avibactam in Klebsiella pneumoniae from a critically ill patient during cefiderocol and ceftazidime/avibactam treatment.
    Amadesi S; Gatti M; Rinaldi M; Pea F; Viale P; Gaibani P
    Int J Antimicrob Agents; 2024 Apr; 63(4):107107. PubMed ID: 38325723
    [No Abstract]   [Full Text] [Related]  

  • 2. Concomitant Resistance to Cefiderocol and Ceftazidime/Avibactam in Two Carbapenemase-Producing
    Bellinzona G; Merla C; Corbella M; Iskandar EN; Seminari E; Di Matteo A; Gaiarsa S; Petazzoni G; Sassera D; Baldanti F; Piazza A; Cambieri P
    Microb Drug Resist; 2024 Jan; 30(1):21-26. PubMed ID: 37870558
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Effect of β-Lactam Antibiotics on the Evolution of Ceftazidime/Avibactam and Cefiderocol Resistance in KPC-Producing Klebsiella pneumoniae.
    Zhang P; Hu H; Shi Q; Sun L; Wu X; Hua X; McNally A; Jiang Y; Yu Y; Du X
    Antimicrob Agents Chemother; 2023 Mar; 67(3):e0127922. PubMed ID: 36794957
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of a KPC Variant Conferring Resistance to Ceftazidime-Avibactam from ST11 Carbapenem-Resistant
    Wu Y; Yang X; Liu C; Zhang Y; Cheung YC; Wai Chi Chan E; Chen S; Zhang R
    Microbiol Spectr; 2022 Apr; 10(2):e0265521. PubMed ID: 35416703
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Changes in KPC-producing
    Boattini M; Bianco G; Comini S; Iannaccone M; Casale R; Charrier L; Cavallo R; Costa C
    Infect Dis (Lond); 2022 Apr; 54(4):311-313. PubMed ID: 34871146
    [No Abstract]   [Full Text] [Related]  

  • 6. Genomic characterisation of a novel KPC-98-producing clinical Klebsiella pneumoniae strain conferring resistance to ceftazidime/avibactam.
    Mendes G; Santos ML; Ramalho JF; Bruschy-Fonseca A; Lito L; Mendes-Pedro D; Duarte A; Melo-Cristino J; Caneiras C
    Int J Antimicrob Agents; 2023 Dec; 62(6):107013. PubMed ID: 37875180
    [No Abstract]   [Full Text] [Related]  

  • 7. Suboptimal drug exposure leads to selection of different subpopulations of ceftazidime-avibactam-resistant Klebsiella pneumoniae carbapenemase-producing Klebsiella pneumoniae in a critically ill patient.
    Gaibani P; Gatti M; Rinaldi M; Crovara Pesce C; Lazzarotto T; Giannella M; Lombardo D; Amadesi S; Viale P; Pea F; Ambretti S
    Int J Infect Dis; 2021 Dec; 113():213-217. PubMed ID: 34656787
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phenotypic and genotypic analysis of KPC-51 and KPC-52, two novel KPC-2 variants conferring resistance to ceftazidime/avibactam in the KPC-producing Klebsiella pneumoniae ST11 clone background.
    Sun L; Chen W; Li H; Li L; Zou X; Zhao J; Lu B; Li B; Wang C; Li H; Liu Y; Cao B
    J Antimicrob Chemother; 2020 Oct; 75(10):3072-3074. PubMed ID: 32719857
    [No Abstract]   [Full Text] [Related]  

  • 9. Emergence of ceftazidime-avibactam resistance through distinct genomic adaptations in KPC-2-producing Klebsiella pneumoniae of sequence type 39 during treatment.
    Galani I; Karaiskos I; Angelidis E; Papoutsaki V; Galani L; Souli M; Antoniadou A; Giamarellou H
    Eur J Clin Microbiol Infect Dis; 2021 Jan; 40(1):219-224. PubMed ID: 32729059
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Emergence of Ceftazidime-Avibactam Resistance Due to Plasmid-Borne
    Shields RK; Chen L; Cheng S; Chavda KD; Press EG; Snyder A; Pandey R; Doi Y; Kreiswirth BN; Nguyen MH; Clancy CJ
    Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 28031201
    [TBL] [Abstract][Full Text] [Related]  

  • 11. KPC-50 Confers Resistance to Ceftazidime-Avibactam Associated with Reduced Carbapenemase Activity.
    Poirel L; Vuillemin X; Juhas M; Masseron A; Bechtel-Grosch U; Tiziani S; Mancini S; Nordmann P
    Antimicrob Agents Chemother; 2020 Jul; 64(8):. PubMed ID: 32457107
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro and in vivo bactericidal activity of ceftazidime-avibactam against Carbapenemase-producing
    Zhang W; Guo Y; Li J; Zhang Y; Yang Y; Dong D; Zhu D; He P; Hu F
    Antimicrob Resist Infect Control; 2018; 7():142. PubMed ID: 30479755
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Klebsiella pneumoniae Carbapenemase Variants Resistant to Ceftazidime-Avibactam: an Evolutionary Overview.
    Hobson CA; Pierrat G; Tenaillon O; Bonacorsi S; Bercot B; Jaouen E; Jacquier H; Birgy A
    Antimicrob Agents Chemother; 2022 Sep; 66(9):e0044722. PubMed ID: 35980232
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro activity of cefiderocol against ceftazidime-avibactam susceptible and resistant KPC-producing Enterobacterales: cross-resistance and synergistic effects.
    Bianco G; Boattini M; Comini S; Iannaccone M; Bondi A; Cavallo R; Costa C
    Eur J Clin Microbiol Infect Dis; 2022 Jan; 41(1):63-70. PubMed ID: 34462816
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Isolation of a Ceftazidime-Avibactam-Resistant
    Shen S; Shi Q; Han R; Guo Y; Yang Y; Wu S; Yin D; Hu F
    Microbiol Spectr; 2022 Feb; 10(1):e0184021. PubMed ID: 35080422
    [No Abstract]   [Full Text] [Related]  

  • 16. Use of Ceftazidime-avibactam for the Treatment of Extensively drug-resistant or Pan drug-resistant Klebsiella pneumoniae in Neonates and Children <5 Years of Age.
    Iosifidis E; Chorafa E; Agakidou E; Kontou A; Violaki A; Volakli E; Christou EI; Zarras C; Drossou-Agakidou V; Sdougka M; Roilides E
    Pediatr Infect Dis J; 2019 Aug; 38(8):812-815. PubMed ID: 31135647
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Co-resistance to ceftazidime-avibactam and cefiderocol in clinical isolates producing KPC variants.
    Poirel L; Sadek M; Kusaksizoglu A; Nordmann P
    Eur J Clin Microbiol Infect Dis; 2022 Apr; 41(4):677-680. PubMed ID: 35088164
    [TBL] [Abstract][Full Text] [Related]  

  • 18. KPC-39-Mediated Resistance to Ceftazidime-Avibactam in a Klebsiella pneumoniae ST307 Clinical Isolate.
    Jousset AB; Oueslati S; Emeraud C; Bonnin RA; Dortet L; Iorga BI; Naas T
    Antimicrob Agents Chemother; 2021 Nov; 65(12):e0116021. PubMed ID: 34606331
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cross-resistance to cefiderocol and ceftazidime-avibactam in KPC β-lactamase mutants and the inoculum effect.
    Hobson CA; Cointe A; Jacquier H; Choudhury A; Magnan M; Courroux C; Tenaillon O; Bonacorsi S; Birgy A
    Clin Microbiol Infect; 2021 Aug; 27(8):1172.e7-1172.e10. PubMed ID: 33915286
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structural insights into the molecular mechanism of high-level ceftazidime-avibactam resistance conferred by CMY-185.
    Kawai A; Shropshire WC; Suzuki M; Borjan J; Aitken SL; Bachman WC; McElheny CL; Bhatti MM; Shields RK; Shelburne SA; Doi Y
    mBio; 2024 Feb; 15(2):e0287423. PubMed ID: 38179965
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.